Eli Lilly (LLY) Current Deferred Tax Assets (2009 - 2010)
Eli Lilly (LLY) reported Current Deferred Tax Assets of $297.8 million for Q3 2010, up 12.93% on a YoY basis from $263.7 million in Q3 2009, and down 5.28% quarter-over-quarter from $314.4 million in Q2 2010.
Eli Lilly (LLY) Current Deferred Tax Assets (2009 - 2010) Analysis & Trends
Eli Lilly has reported Current Deferred Tax Assets for 2 years, with the latest figure at $297.8 million in Q3 2010.
- For the quarter ending Q3 2010, Current Deferred Tax Assets rose 12.93% year-over-year to $297.8 million; the trailing twelve-month figure through Sep 2010 stood at $297.8 million (up 12.93% YoY), and the FY2009 full-year result was $271.0 million, changed N/A from the prior year.
- Current Deferred Tax Assets for Q3 2010 stood at $297.8 million, down from $314.4 million in the prior quarter.
- The five-year high for Current Deferred Tax Assets was $314.4 million in Q2 2010, with the low at $263.7 million in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | 297.80 Mn |
| Sep 30, 2010 | 297.80 Mn |
| Jun 30, 2010 | 314.40 Mn |
| Jun 30, 2010 | 314.40 Mn |
| Mar 31, 2010 | 275.20 Mn |
| Mar 31, 2010 | 275.20 Mn |
| Dec 31, 2009 | 271.00 Mn |
| Dec 31, 2009 | 271.00 Mn |
| Sep 30, 2009 | 263.70 Mn |
| Sep 30, 2009 | 263.70 Mn |
| Jun 30, 2009 | 290.60 Mn |
| Jun 30, 2009 | 290.60 Mn |